基于对比增强MRI的影像组学分析预测肝细胞癌载药微球经动脉化疗栓塞短期疗效
本回顾性队列研究纳入113例中晚期肝细胞癌患者,基于对比增强MRI动脉期、扩散加权成像和T2加权成像提取5343个特征,采用LASSO回归筛选特征并构建临床-影像组学联合模型,用于术前预测首次载药微球经动脉化疗栓塞的短期疗效。联合模型预测效能最佳,训练集AUC=0.902、测试集AUC=0.845,且不同预测疗效组间无进展生存期存在差异。
要点
- 临床-影像组学联合模型预测首次D-TACE短期疗效最佳,训练集AUC=0.902、测试集AUC=0.845。
- 四类影像组学模型中基于动脉期的模型预测效能最佳,训练集AUC=0.89、测试集AUC=0.85。
- 微球类型(p=0.042)和动脉期Rad-score(p=0.01)与短期疗效相关。
核心结论
- 临床-影像组学联合模型可有效预测肝细胞癌患者首次D-TACE的短期疗效,有助于为患者带来临床和经济获益。
研究设计与样本
- 回顾性队列研究,纳入113例中晚期肝细胞癌患者,基于对比增强MRI的动脉期、扩散加权成像和T2加权成像三个序列提取5343个特征。
诊断标准与关键数值
- LASSO回归共筛选出34个影像组学特征;临床-影像组学联合模型训练集AUC=0.902、测试集AUC=0.845;基于动脉期的影像组学模型训练集AUC=0.89、测试集AUC=0.85;多因素logistic回归显示微球类型(p=0.042)和动脉期Rad-score(p=0.01)与短期疗效相关。
临床应用与阅片要点
- 联合模型预测的不同短期疗效组间无进展生存期存在差异,且客观缓解组预后优于非客观缓解组。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: We developed and validated a clinical-radiomics model for preoperative prediction of the short-term efficacy of initial drug-eluting beads transarterial chemoembolization (D-TACE) treatment in patients with hepatocellular carcinoma (HCC).
METHODS: In this retrospective cohort study of 113 patients with intermediate and advanced HCC, 5343 features were extracted based on three sequences of the arterial phase (AP), diffusion-weighted imaging, and T2-weighted images based on contrast-enhanced magnetic resonance imaging, and minimum redundancy maximum correlation and least absolute shrinkage and selection operator (LASSO) regression were applied for feature selection and model construction. Multifactor logistic regression was used to build a clinical-imaging model based on clinical factors and a clinical-radiomics model. The area under the curve (AUC) and calibration curves were used to assess model performance, and the clinical value of the model was analyzed using decision curve analysis. The relationship between the actual and predicted short-term efficacy of the combined model and progression-free survival (PFS) was evaluated using Kaplan-Meier survival curves and log-rank tests.
RESULTS: A total of 34 radiomics features were selected by LASSO, and the clinical-radiomics model had the best predictive performance (AUC = 0.902 and AUC = 0.845 for the training and testing sets, respectively), and the model based on AP had the best predictive performance among the four radiomics models (AUC = 0.89 for the training set and AUC = 0.85 for the testing set); the multifactorial logistic regression results showed that microsphere type (p = 0.042) and AP Rad-score (p = 0.01) were associated with short-term efficacy. In addition, a difference in PFS was observed in patients with HCC with different short-term efficacies predicted by the combined model. Moreover, prognosis was better in the objective versus non-objective response group.
CONCLUSIONS: The combined clinical-radiomics model is an effective predictor of the short-term efficacy of initial D-TACE in patients with HCC, contributing to clinical and economic benefits for patients.
引用
- Xi Z, Ye Y, Yang Y, et al. Radiomics analysis based on contrast-enhanced MRI for predicting short-term efficacy of drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma. Abdom Radiol (NY). 2024. PMID: 39030402. doi:10.1007/s00261-024-04319-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。